Radioiodine is commonly used to treat differentiated thyroid carcinoma. Nonetheless, the high activities administered during therapy are potentially carcinogenic for other organs, such as the salivary glands and digestive tract. The risk of second primary malignancies after radioiodine therapy for thyroid carcinoma is discussed by the author of this Viewpoint.
